Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10]. Core Insights - The medical and biological sector experienced a decline of 3.31% this week, ranking 22nd among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index rose by 0.08%, indicating that the medical sector underperformed by 3.39 percentage points [2][12]. - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, 2026, aiming to enhance drug research, registration, and production management, thereby fostering innovation in the pharmaceutical industry [5][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 33.87X, with a Price-to-Book (PB) ratio of 3.43X, reflecting a decrease from the previous week [4][30]. Summary by Sections Industry Performance - The medical services sub-sector closed at 7122.75 points, down 4.15% this week, while the overall medical and biological sector fell by 3.31% [2][24]. - Notable performers in the medical services sector included Tigermed (+4.3%) and Prasis (+2.3%), while underperformers included Bid Pharma (-15.2%) and Haoyuan Pharma (-12.8%) [3][28]. Valuation Metrics - The medical services sector's PE ratio has decreased by 1.43X from the previous week, while the PB ratio has dropped by 0.15X [4][30]. - The maximum and minimum PE ratios over the past year were 41.13X and 28.46X, respectively, while the PB ratios ranged from 4.00X to 2.48X [30][49]. Regulatory Developments - The new drug administration regulations aim to support drug innovation and streamline the drug approval process, including provisions for market exclusivity for certain drugs [5][63]. - The regulations are expected to stimulate the CXO (Contract Research Organization) industry, enhancing demand for preclinical research and clinical trials [9][63]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharma, as well as companies in the consumer healthcare sector like Aier Eye Hospital and Dian Diagnostics, which are expected to see improvements in profitability [10][64].

医药周报 20260130 从 JPM 大会挖掘 FIC 靶点三期数据验证节点 glmszqdatemark 医药行情回顾&分析&近期判断 周专题：从 JP Morgan 大会看 2026 MNC 密集验证新靶点 风险提示：1）医保、集采政策导致价格不及预期；2）临床进度或上市时间不及预期；3）行业竞争 格局的不确定性；4）地缘政治风险；5）下游投融资及需求复苏不及预期。 2026 年 02 月 01 日 推荐 维持评级 [Table_Author] | 分析师 张金洋 | | --- | | 执业证书： S0590525120012 | | 邮箱： zhangjinyang@glms.com.cn | | 分析师 胡偌碧 | | 执业证书： S0590525120011 | | 邮箱： huruobi@glms.com.cn | | 分析师 王彦迪 | | 执业证书： S0590525120015 | | 邮箱： wangyandi@glms.com.cn | 相对走势 -10% 7% 23% 40% 2025/2 2025/8 2026/1 医药 沪深300 相关研究 本公司具备证券投资咨询业务资格，请务 ...

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical industry [3] Core Insights - The report highlights the focus on innovation and internationalization within the pharmaceutical industry, with an emphasis on the development of innovative drugs and the exploration of new technological avenues [9][41] - The report suggests a dual investment strategy: one focusing on the rotation of technological innovation from 0 to 1 and the other on value recovery, emphasizing stocks with reasonable valuations and performance growth catalysts [9] - Key investment opportunities are identified in the CRO sector, with specific companies recommended for attention, including Tigermed, Baioo, and WuXi AppTec [9] Summary by Sections 1. Insights from JP Morgan Conference - The report discusses several new therapeutic targets presented at the JP Morgan conference, including Lp(a) siRNA therapy, FXI monoclonal antibodies, and TL1A monoclonal antibodies, all expected to yield phase III data in 2026 [12][18][22][34] - Notably, the Lp(a) siRNA drug Pelacarsen aims to reduce cardiovascular risks associated with Lp(a) levels through a novel mechanism [12][15] - FXI monoclonal antibodies are being developed for stroke prevention in atrial fibrillation patients, with promising data expected in 2026 [18][20] - TL1A monoclonal antibodies are being explored for ulcerative colitis, with data readouts anticipated in 2026 [22] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index experienced a week-over-week decline of 3.31%, underperforming both the ChiNext and CSI 300 indices [41] - The total trading volume for pharmaceuticals was 685.97 billion yuan, accounting for 4.52% of the total market, which is below the historical average of 7.10% [62] - The report notes that the pharmaceutical sector's valuation is currently below the historical average, with a PE ratio of 29.40, indicating a relative undervaluation [58] 3. Individual Stock Performance - The report lists the top-performing stocks for the week, including Cap Bio and Hualan Biological, while highlighting underperformers such as *ST Sailong and Hexin Instruments [66] - Monthly performance rankings show significant gains for stocks like Hongbo Pharmaceutical and Baolait, while others like Hezhong China faced substantial declines [66]

智通财经APP获悉，瑞银发布研报称，现予泰格医药(03347)目标价57.1港元及"买入"评级。泰格医药发 布业绩预告，料2025年度营业收入同比增长1%至16%，意味第四季收入同比增长6.4%至72.9%，中位数 升39.6%高过该行及市场预期。不过，归属股东净利润预计为8.3亿至12.3亿元人民币，同比升105%至 204%，则低过该行及市场预期。 公司指，2025年新签订单的价格趋于稳定，但仍同比下滑，对利润率构成压力，公司同时强调临床研发 需求正复苏。瑞银关注泰格医药2026年新签订单的价格复苏讯号，以及管理层对2026年收入及利润的指 引。 ...

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [12][60]. Core Insights - The report highlights significant collaborations in the innovative drug sector, including 石药集团 (Shijiazhuang Yiling Pharmaceutical) partnering with AstraZeneca for long-acting peptide drug development and receiving clinical trial approval for SYS6055 injection in China [8][37]. - The report emphasizes the robust R&D capabilities of Chinese pharmaceutical companies showcased at the 2026 JPM Healthcare Conference, suggesting investment opportunities in innovative drugs, CXO, and upstream life sciences [12][60]. - The report notes the recent release of the revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China," which aims to enhance drug innovation and regulatory processes [19][20]. Industry Data - As of January 29, 2026, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) is 51.60 times, with a valuation premium of 259% relative to the CSI 300 index [10][52]. - The report provides current prices for vitamin raw materials, with Vitamin B1 at 237.5 RMB/kg and Vitamin D3 at 130 RMB/kg, remaining stable compared to January 28 [22]. - The Chinese herbal medicine market index shows a decline of 15% year-on-year, with specific herbs like 党参 (Codonopsis) and 当归 (Angelica) experiencing price drops of 41% and 29% respectively [26]. Company Announcements - 先声药业 (Xiansheng Pharmaceutical) signed an exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, with potential milestone payments reaching up to 1.016 billion euros [36]. - 恒瑞医药 (Hengrui Medicine) received acceptance for a drug listing application and clinical trial approval for multiple products, including a breakthrough therapy designation for HRS-5346 [39][40]. - 诺诚健华 (Innovent Biologics) anticipates a revenue of approximately 2.365 billion RMB for 2025, marking a 134% year-on-year increase [41].

Market Overview - Recent surge in precious metals led to market excitement, but a sharp decline followed, with Hong Kong stocks dropping 2.08% [1] - International gold and silver prices experienced volatility, with gold surpassing $5,500 per ounce before falling below $5,200 [2] - Resource stocks, including those in gold and copper, saw significant declines, with companies like Zhaifeng Gold and Shandong Gold dropping over 14% [2] Geopolitical Developments - Trump announced plans to engage in dialogue with Iran, contingent on Iran not possessing nuclear weapons and ceasing repression of protesters, which may temporarily stabilize oil prices [1] - The U.S. Federal Reserve chair nomination is expected to favor a hawkish candidate, potentially leading to a stronger dollar [1] Corporate News - Longfor's subsidiary faced a ruling from Panama's Supreme Court declaring its port contracts unconstitutional, impacting its $22.8 billion global port asset sale [2][3] - The Chinese Foreign Ministry stated it would take measures to protect the rights of Chinese enterprises affected by the ruling [3] Sector Focus - AI investments are gaining traction, with OpenAI planning an IPO and Alibaba considering increasing its AI and cloud investment to 480 billion RMB over three years [3] - Companies like Changfei Optical Fiber and Cable saw stock increases of over 6% due to positive developments in the optical communication sector [3] Battery Technology - CATL launched sodium-ion battery products, which outperform lithium batteries in low-temperature environments and safety [4] - The introduction of sodium batteries could disrupt the lithium battery market, with companies like Ganfeng Lithium and Tianqi Lithium experiencing declines of over 10% [5] Earnings Reports - Tiger Med announced expected revenue of 6.66 to 7.68 billion RMB for 2025, with a net profit forecast of 830 million to 1.23 billion RMB, reflecting strong growth [5] - Shanghai Fudan anticipates a revenue increase of approximately 9.46% to 12.25% for 2025 [5] Film Industry Developments - The National Film Development Fund is promoting high-quality development in the film industry, with several new films set to release during the 2026 Spring Festival [6] - Beneficiaries include companies like Dama Entertainment and Maoyan Entertainment, involved in producing and distributing upcoming films [7] AI Growth - Kuaishou's AI product, Keling, has seen significant user growth, with monthly active users surpassing 12 million and a 350% increase in paid users [8] - The company expects substantial revenue growth, with projections of $140 million for 2025, significantly exceeding initial targets [9]

Group 1 - The core index of the biotechnology sector (970038) closed at 2205.04 points, down 0.85%, with a trading volume of 33.22 billion yuan and a turnover rate of 3.61% [1] - Among the constituent stocks, 10 companies experienced an increase, with Tigermed leading the gain at 6.96%, while 40 companies saw a decline, with Dian Diagnostics leading the drop at 4.63% [1] Group 2 - The net outflow of main funds from the biotechnology index constituent stocks totaled 69.18 million yuan, while the net inflow of speculative funds was 134 million yuan, and the net outflow of retail funds was 64.63 million yuan [2] - Detailed fund flow information for the constituent stocks is available in the accompanying table [2]

Group 1 - The top three companies with the highest short position ratios are China COSCO Shipping (01919) at 17.74%, Vanke (02202) at 17.56%, and Dongfang Electric (01072) at 17.36% [1][2] - The companies with the largest absolute increase in short position ratios are Neway Group (01686) with an increase of 2.33%, China Ship Leasing (03877) with an increase of 2.23%, and Pacific Shipping (02343) with an increase of 1.78% [1][2] - The companies with the largest absolute decrease in short position ratios are Zhaoyan New Drug (06127) with a decrease of -1.92%, Lens Technology (06613) with a decrease of -1.51%, and Country Garden (02007) with a decrease of -1.48% [1][3] Group 2 - The latest short position ratios for the top ten companies show China COSCO Shipping (01919) at 17.74%, Vanke (02202) at 17.56%, and Dongfang Electric (01072) at 17.36% [2] - The companies with the largest increases in short position ratios include Neway Group (01686) from 3.65% to 5.99%, China Ship Leasing (03877) from 0.74% to 2.97%, and Pacific Shipping (02343) from 5.02% to 6.80% [2] - The companies with the largest decreases in short position ratios include Zhaoyan New Drug (06127) from 7.94% to 6.02%, Lens Technology (06613) from 8.32% to 6.80%, and Country Garden (02007) from 3.02% to 1.54% [3][4]

Core Viewpoint - The Xinhua 500 Index (989001) experienced a decline of 62.15 points, or 1.16%, closing at 5306.68 points on January 30, 2025 [1]. Market Performance - The Xinhua 500 Index opened lower on January 30, initially dropping approximately 1.95% before rebounding slightly, ultimately closing significantly down [3]. - The index reached a high of 5350.53 points and a low of 5229.75 points during the trading session [4]. - The total trading volume for constituent stocks was reported at 10,624 billion yuan, showing a significant decrease compared to the previous trading day [4]. Stock Movements - Notable gainers included Lanke Technology, which rose by 12.13%, and several stocks such as Huanyu Electronics and Hengtong Optic-Electric reached around 10% limit up [4]. - Conversely, multiple stocks including Nanshan Aluminum and Tongling Nonferrous Metals experienced around 10% limit down [4]. Weekly Performance - The Xinhua 500 Index recorded a cumulative decline of 0.57% for the week from January 26 to January 30, 2025 [5].

大摩又指，集团管理层对行业前景保持乐观，而近期的一次会议上，管理层提到中国CRO行业似乎正 处于复苏态势。 摩根士丹利表示，强劲的盈利增长主要归因于泰格医药资产的大幅重估，以及2024年相对较低的基数。 尽管受订单取消及收款困难影响，集团经常性收益表现疲软，但公司新订单增长依然强劲。扣除取消订 单后的新增在手订单净额介于95亿元至105亿元，同比增长13%至25%。 智通财经APP获悉，摩根士丹利发布研报称，泰格医药(03347)公布2025年初步业绩，营收介乎为66.6亿 元至76.8亿元人民币(下同)，同比增长1%至16%。该范围较摩根士丹利预估为低2%至高12%。净利润介 乎8.3亿元至12.3亿元，同比增长105%至增长204%。予泰格医药(300347.SZ)A股目标价81元，评级"增 持"。 ...